| Hans-Günter Meyer-Thompson | Verschiedene
First-in-kind psychedelic trials to treat opioid and methamphetamine use disorders
First-in-kind psychedelic trials to treat opioid and methamphetamine use disorders
Three million people in the United States have had opioid use disorder, and another 1.5 million people have dealt with methamphetamine misuse within the last year alone.
But two new clinical trials out of the UW Transdisciplinary Center for Research in Psychoactive Substances (TCRPS), housed within the University of Wisconsin–Madison School of Pharmacy, aim to address these pressing issues with a promising psychoactive agent: psilocybin. (MedicalXpress, USA, 09.01.2023)
https://medicalxpress.com/news/2023-01-first-in-kind-psychedelic-trials-opioid-methamphetamine.html